Anebulo Pharmaceuticals, Inc. financial data

Symbol
ANEB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Jfl Capital Management, 1017 Rr 620 S, Suite 107, Lakeway, Texas
State of incorporation
Delaware
Fiscal year end
June 30
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12.5 % +92.6%
Return On Equity -123 % -66.6%
Return On Assets -109 % -57.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.9 M shares +1.17%
Common Stock, Shares, Outstanding 25.9 M shares +1.17%
Entity Public Float 9.47 M USD -80.9%
Common Stock, Value, Issued 25.9 K USD +1.17%
Weighted Average Number of Shares Outstanding, Basic 25.9 M shares +1.17%
Weighted Average Number of Shares Outstanding, Diluted 25.9 M shares +1.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.5 M USD -15.1%
General and Administrative Expense 4.96 M USD -21.4%
Operating Income (Loss) -9.46 M USD +18.5%
Nonoperating Income (Expense) 116 K USD -83.8%
Net Income (Loss) Attributable to Parent -9.35 M USD +19.1%
Earnings Per Share, Basic 0.57 USD/shares +375%
Earnings Per Share, Diluted 0.57 USD/shares +45.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.15 M USD
Assets, Current 5.37 M USD
Other Assets, Noncurrent 625 K USD
Assets 6 M USD -58.5%
Accounts Payable, Current 385 K USD -32.6%
Accrued Liabilities, Current 625 K USD -32%
Liabilities 1.01 M USD -32.2%
Retained Earnings (Accumulated Deficit) -64.1 M USD -17.1%
Stockholders' Equity Attributable to Parent 4.99 M USD -61.5%
Liabilities and Equity 6 M USD -58.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.73 M USD -34.1%
Net Cash Provided by (Used in) Financing Activities 6.38 M USD
Common Stock, Shares Authorized 50 M shares +25%
Common Stock, Shares, Issued 25.9 M shares +1.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.73 M USD -158%
Deferred Tax Assets, Valuation Allowance 4.69 M USD +110%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 4.69 M USD +110%
Deferred Tax Assets, Operating Loss Carryforwards 2.87 M USD +55.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2 M shares 0%
Additional Paid in Capital 69 M USD +2.06%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 59.7 K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%